Beta Drugs Limited has announced an Extraordinary General Meeting (EGM) scheduled for Wednesday, February 4, 2026, at its registered office in Baddi, Himachal Pradesh, commencing at 11:30 a.m.

The primary agenda for the EGM includes seeking shareholder approval to increase the company's authorized share capital from ₹11 crore to ₹11.40 crore. This increase will result in a rise in the total number of equity shares from 1.10 crore to 1.14 crore, each with a face value of ₹10.

Additionally, the shareholders will be asked to approve the 'Beta Drugs Limited Employee Stock Option Plan 2026' (ESOP 2026). This plan allows for the grant of stock options exercisable into up to 2,00,000 equity shares, representing 1.98% of the company's paid-up equity shares as of March 31, 2025. The benefits of this ESOP will also be extended to employees of the company's group entities, including holding, subsidiary, and associate companies.

Furthermore, the EGM will consider and approve the issuance and allotment of 2,83,668 equity shares of face value ₹10 each, at a price of ₹1712.49 per share (including a premium of ₹1702.49), on a preferential basis. This issuance is part of a share swap arrangement where equity shares held by proposed allottees in Nivian Lifesciences Private Limited will be transferred to Beta Drugs Limited prior to the allotment. The total value of this preferential issue is approximately ₹48.57 crore, with the consideration for the shares being transferred valued at approximately ₹69.39 crore.